The Helicobacter pylori Genome Project and Gastric Cancer Research at the US National Cancer Institute.

Christian Abnet, PhD, MPH

Senior Investigator Director, Metabolic Epidemiology Branch Senior Advisor for Cancer Genomics Research

Division of Cancer Epidemiology & Genetics



Gastric Cancer Research at NCI

 NCI is a very large research institution and here I will focus on the intramural work in the Division of Cancer Epidemiology and Genetics

- A full report on NCI's support of gastric and esophageal cancer can be had here:
 - https://deainfo.nci.nih.gov/advisory/ctac/workgroup/ctacsup mat.htm

Gastric Cancer Research in DCEG

- Gastric cancer prevention trials
- Descriptive epidemiology
- Etiologic research
- H. pylori Genome Project (HpGP)

NCI-sponsored gastric cancer prevention trials

Two separate trials conducted in different parts of China

Nutrition Intervention Trial

Prevention of esophageal and gastric cancer

Shandong Intervention Trial

Prevention of progression of preneoplastic lesions


Nutrition Intervention Trials in Linxian, China: Supplementation With Specific Vitamin/Mineral Combinations, Cancer Incidence, and Disease-Specific Mortality in the General Population

William J. Blot, Jun-Yao Li, Philip R. Taylor, Wande Guo, Sanford Dawsey, Guo-Qing Wang, Chung S. Yang, Su-Fang Zheng, Mitchell Gail, Guang-Yi Li, Yu Yu, Buo-qi Liu, Joseph Tangrea, Yu-hai Sun, Fusheng Liu, Joseph F. Fraumeni, Jr., You-Hui Zhang, Bing Li*

Journal of the National Cancer Institute, Vol. 85, No. 18, September 15, 1993

Table 1. Types and daily doses of micronutrients by treatment factor

Factor	Micronutrients	Dose per day
A	Retinol (as palmitate)	5000 IU
	Zinc (as zinc oxide)	22.5 mg
В	Riboflavin	3.2 mg
	Niacin	40 mg
С	Ascorbic acid	120 mg
	Molybdenum (as molybdenum yeast complex)	30 дд
D	Beta carotene	15 mg
	Selenium (as selenium yeast)	50 µg
	Alpha-tocopherol	30 mg



Effects of Nutrition Intervention on Total and Cancer Mortality: 25-Year Post-trial Follow-up of the 5.25-Year Linxian Nutrition Intervention Trial

Shao-Ming Wang*, Philip R. Taylor, Jin-Hu Fan*, Ruth M. Pfeiffer, Mitchell H. Gail, He Liang, Gwen A. Murphy, Sanford M. Dawsey, You-Lin Qiao, Christian C. Abnet

JNCI J Natl Cancer Inst (2018) 110(11): djy043

Randomized Double-Blind Factorial Trial of Three Treatments To Reduce the Prevalence of Precancerous Gastric Lesions

Wei-cheng You, Linda M. Brown, Lian Zhang, Ji-you Li, Mao-lin Jin, Yun-shen Chang, Jun-ling Ma, Kai-feng Pan, Wei-dong Liu, Yuanreng Hu, Susan Crystal-Mansour, David Pee, William J. Blot, Joseph F. Fraumeni Jr., Guang-wei Xu, Mitchell H. Gail

	Dysplasia or gastric cancer		Severe chronic atrophic gastritis, intestinal metaplasia, dysplasia, or gastric cancer		Average severity score				
Year, treatment group	OR (95% CI)	P	OR (95% CI)	\overline{P}	Active	Placebo	Difference (95% CI)	P^{\dagger}	
1999									
H. pylori treatment	1.13 (0.89 to 1.44)	.32	0.77 (0.62 to 0.95)	.016	4.14	4.22	-0.08 (-0.21 to 0.05)	.22	
Vitamins	1.10 (0.89 to 1.37)	.39	1.32 (1.12 to 1.57)	.001	3.97	3.87	0.10 (-0.01 to 0.21)	.068	
Garlic	0.98 (0.79 to 1.22)	.86	0.99 (0.84 to 1.18)	.94	3.93	3.92	0.01 (-0.10 to 0.12)	.84	
2003									
H. pylori treatment	1.07 (0.88 to 1.31)	.49	0.60 (0.47 to 0.75)	<.001	4.45	4.69	-0.24 (-0.40 to -0.09)	.002	
Vitamins	1.03 (0.87 to 1.23)	.71	1.14 (0.96 to 1.37)	.14	4.29	4.23	0.06 (-0.08 to 0.20)	.38	
Garlic	1.02 (0.86 to 1.21)	.83	1.08 (0.90 to 1.29)	.40	4.26	4.25	0.01 (-0.12 to 0.15)	.83	

Journal of the National Cancer Institute, Vol. 98, No. 14, July 19, 2006

Effects of *Helicobacter pylori* treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial

Wen-Qing Li, Iing-Yu Zhang, Iun-Ling Ma, Zhe-Xuan Li, Lian Zhang, Yang Zhang, Yang Guo, Tong Zhou, Ji-You Li, Lin Shen, Wei-Dong Liu, Zhong-Xiang Han, William J Blot, Albert Mitchell H Gail, Kai-Feng Pan, Wei-Cheng You

Table 2 | Odds ratios (95% confidence intervals) for incidence of gastric cancer by *Helicobacter pylori* treatment, and vitamin and garlic supplementation

	Adjusted for baseling	ne histology			Fully adjusted*			
Interventions	Placebo (No with event/No in group)	Treatment (No with event/No in group)	Odds ratio (95% CI)	P value	Placebo (No with event/No in group)	Treatment (No with event/No in group)	Odds ratio (95% CI)	P value
H pylori treatment	78/1123	40/1119	0.48 (0.33 to 0.72)	<0.001	76/1086	40/1086	0.48 (0.32 to 0.71)	<0.001
Vitamin supplementation	90/1679	60/1665	0.66 (0.47 to 0.92)	0.02	89/1627	58/1610	0.64 (0.46 to 0.91)	0.01
Garlic supplementation	82/1678	68/1666	0.82 (0.58 to 1.14)	0.23	81/1631	66/1606	0.81 (0.57 to 1.13)	0.22

Number of participants and number of gastric cancer cases is lower than in table 1 because of missing information on baseline histology or other covariates.

^{*}Adjusted for baseline histology (moderate chronic atrophic gastritis or less severe gastric lesions, severe chronic atrophic gastritis or superficial intestinal metaplasia, deep intestinal metaplasia, or dysplasia), age, sex, history of ever using alcohol, and history of ever smoking.

Fully adjusted*			
Placebo (No with event/No in group)	Treatment (No with event/No in group)	Odds ratio (95% CI)	P value
76/1086	40/1086	0.48 (0.32 to 0.71)	<0.001
89/1627	58/1610	0.64 (0.46 to 0.91)	0.01
81/1631	66/1606	0.81 (0.57 to 1.13)	0.22

the**bmj** | *BMJ* 2019;366:l5016 | doi: 10.1136/bmj.l5016


Gastric Cancer Research in DCEG

- Gastric cancer prevention trials
- Descriptive epidemiology
- Etiologic research
 - The role of Helicobacter pylori in gastric cancer by subsite and geographic location
- H. pylori Genome Project (HpGP)

The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites

William F. Anderson, Charles S. Rabkin, Natalie Turner, Joseph F. Fraumeni Jr., Philip S. Rosenberg, M. Constanza Camargo

JNCI J Natl Cancer Inst (2018) 110(6): djx262





J Natl Cancer Inst (2018)

Sex and age differences in mortality trends of gastric cancer among Hispanic/Latino populations in the United States, Latin America, and the Caribbean

J. Smith Torres-Roman, ^{a,b}* Christian S. Alvarez, ^c Pedro Guerra-Canchari, ^{b,d} Bryan Valcarcel, ^b José Fabián Martinez-Herrera, ^{b,e} Carlos A. Dávila-Hernández, ^f Camila Alves Santos, ^{b,g} Samara Carollyne Mafra Soares, ^{b,g} Dyego Leandro Bezerra de Souza, ^{b,g,h} and M. Constanza Camargo ^c

The Lancet Regional Health - Americas 2022;16: 100376 Published online 7 October 2022 https://doi.org/10.1016/j. lana.2022.100376

Gastric Cancer Research in DCEG

- Gastric cancer prevention trials
- Descriptive epidemiology
- Etiologic research
 - The role of Helicobacter pylori in gastric cancer by subsite and geographic location
- H. pylori Genome Project (HpGP)

- Gastric cardia tumors
 - occur in the top few centimeters of the stomach
 - clinically and histologically, they are difficult to separate from esophageal adenocarcinomas


 Mistakenly thought to be primarily a tumor of White men of European origin

Global burden of oesophageal and gastric cancer by histology and subsite in 2018

Melina Arnold , ¹ Jacques Ferlay, ¹ Mark I van Berge Henegouwen , ² Isabelle Soerjomataram

Arnold M, et al. Gut 2020;**69**:1564–1571. doi:10.1136/gutjnl-2020-321600

For both CGC and NCGC, the vast majority of cases occurred in Asia, together representing over 70% of the global case burden of both subsites (figure 1). In the case of CGC, about 121000 cases (67%) occurred in Eastern Asia (whereof 110000 in China), followed by South Central Asia (14000 cases, 8%) and Northern America (9000 cases, 5%).



Arnold M, et al. Gut 2020;69:1564-1571. doi:10.1136/gutjnl-2020-321600

Gastric cancer and *Helicobacter pylori*: a combined analysis of 12 case control studies nested within prospective cohorts

Gut 2001;49:347-353

Helicobacter and Cancer Collaborative Group

Gastric cancer and H pylori

S M Dawsey, S D Mark, P R Taylor National Cancer Institute, Bethesda, MD, USA

> P J Limburg Mayo Clinic, Rochester, MN, USA

Gut 2002;51:455-458

Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China

```
F Kamangar*,<sup>1</sup>, Y-L Qiao*,<sup>2</sup>, MJ Blaser<sup>3,4</sup>, X-D Sun<sup>2</sup>, H Katki<sup>1</sup>, J-H Fan<sup>2</sup>, GI Perez-Perez<sup>3,4</sup>, CC Abnet<sup>1</sup>, P Zhao<sup>2</sup>, SD Mark<sup>5</sup>, PR Taylor<sup>1</sup> and SM Dawsey<sup>1</sup>
```

	Number tested	Adjusted HR ^a (95% CI)
Subcohort	992	_
Oesophageal squamous cell cancer	335	1.17 (0.88-1.57)
Gastric cardia cancer	582	1.64 (1.26-2.14)
Gastric non-cardia cancer	343	1.60 (1.15-2.21)

Multiplex *H. pylori* Serology and Risk of Gastric Cardia and Noncardia Adenocarcinomas



Ramin Shakeri¹, Reza Malekzadeh¹, Dariush Nasrollahzadeh^{1,2}, Michael Pawilta³, Gwen Murphy⁴, Farhad Islami^{1,5}, Masoud Sotoudeh¹, Angelika Michel³, Arash Etemadi^{1,4}, Tim Waterboer³, Hossein Poustchi⁶, Paul Brennan⁷, Paolo Boffetta⁸, Sanford M. Dawsey⁴, Farin Kamangar^{1,9}, and Christian C. Abnet⁴

	Gastric cardia adenocarcinoma				Gastric noncardia adenocarcinoma				
		Controls	Unadjusted	Adjusted ^a		Controls	Unadjusted	Adjusted ^a OR	
,	N (%)	N (%)	OR (95% CI)	OR (95% CI)	N (%)	N (%)	OR (95% CI)	(95% CI)	
,	142	276			103	195			
Whole cell ELISA	11 (7.7) 131 (92.3)	20 (7.2) 131 (92.8)	1 0.9 (0.4-1.9)	1.3 (0.5-3.1)	6 (5.8) 97 (94.2)	19 (9.7) 176 (90.3)	1 1.7 (0.6-4.3)	1.3 (0.4-3.7)	
CagA	17 (12.0) 125 (88.0)	56 (20.3) 220 (79.7)	1 1.9 (1.1-3.4)	1 2.1 (1.1-4.1)	9 (8.7) 94 (91.3)	47 (24.1) 148 (75.9)	1 3.1 (1.4-6.5)	3.5 (1.4-8.2)	

Original Article

Population Attributable Fraction of *Helicobacter pylori* Infection—Related Gastric Cancer in Korea: A Meta-Analysis

Yoon Park, Moran Ki



2.17 (1.04-4.55)

1.97 (1.02-2.22)

Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

Catherine de Martel, Damien Georges, Freddie Bray, Jacques Ferlay, Gary M Clifford

	Men	Men			Total	Total		
	New cases	New cases attributable to infectious pathogens	New cases	New cases attributable to infectious pathogens	New cases	New cases attributable to infectious pathogens		
Helicobacter pylori								
Non-cardia gastric cancer	550 000	490 000	300 000	270 000	850 000	760 000		
Cardia gastric cancer	130 000	27 000	46 000	8900	180 000	36 000		
Non-Hodgkin lymphoma of gastric location	12 000	8700	10 000	7600	22 000	16 000		

Noncardia Gastric Cancer = 89% Cardia Gastric Cancer = 20%

www.thelancet.com/lancetgh Vol 8 February 2020

Gastric Cancer Research in DCEG

- Gastric cancer prevention trials
- Descriptive epidemiology
- Etiologic research
- Genome Wide Association Studies (GWAS)
- H. pylori Genome Project (HpGP)

nature communications



Article

https://doi.org/10.1038/s41467-023-43562-y

The *Helicobacter pylori* Genome Project: insights into *H. pylori* population structure from analysis of a worldwide collection of complete genomes


Received: 5 September 2023

Accepted: 13 November 2023

Published online: 11 December 2023

Kaisa Thorell ^{1,204} M, Zilia Y. Muñoz-Ramírez ^{2,204}, Difei Wang^{3,4}, Santiago Sandoval-Motta^{5,6,7}, Rajiv Boscolo Agostini⁸, Silvia Ghirotto⁸, Roberto C. Torres ⁹, HpGP Research Network*, Daniel Falush ⁹, M. Constanza Camargo ^{4,205} & Charles S. Rabkin^{4,205}

Kaisa Thorell 61.204 Z. Zilia Y. Muñoz-Ramírez 62.204, Difei Wang 3,4, Santiago Sandoval-Motta 5,6,7, Rajiv Boscolo Agostini8, Silvia Ghirotto⁸, Roberto C. Torres ⁹, Judith Romero-Gallo¹⁰, Uma Krishna¹⁰, Richard M. Peek Jr¹⁰, M. Blanca Piazuelo¹⁰, Naïma Raaf¹¹, Federico Bentolila¹², Hafeza Aftab¹³, Junko Akada¹⁴, Takashi Matsumoto¹⁴, Freddy Haesebrouck¹⁵, Rony P. Colanzi¹⁶, Thais F. Bartelli¹⁷, Diana Noronha Nunes¹⁷, Adriane Pelosof¹⁷, Claudia Zitron Sztokfisz¹⁷, Emmanuel Dias-Neto¹⁷, Paulo Pimentel Assumpção¹⁸, Ivan Tishkov¹⁹, Laure Brigitte Kouitcheu Mabeku²⁰, Karen J. Goodman²¹, Janis Geary²¹, Taylor J. Cromarty²¹, Nancy L. Price²¹, Douglas Quilty²², Aleiandro H. Coryalan²³ Carolina A. Serrano²⁴, Robinson Gonzalez²⁵, Arnoldo Riquelme²⁵, Apolinaria García-Cancino²⁶, Cristian Parra-Sepúlveda²⁶, Giuliano Bernal²⁷, Francisco Castillo²⁸, Alisa M, Goldstein⁴, Nan Hu⁴, Philip R, Taylor⁴, Maria Mercedes Bravo²⁹, Alvaro Pazos³⁰, Luis E. Bravo³¹, Keith T. Wilson¹⁰, James G. Fox³², Vanessa Ramírez-Mayorga³³, Silvia Molina-Castro³³, Sundry Durán-Bermúdez³⁴, Christian Campos-Núñez³⁵, Manuel Chaves-Cervantes³⁵, Evariste Tshibangu-Kabamba^{36,37}, Ghislain Disashi Tumba³⁷, Antoine Tshimpi-Wola³⁸, Patrick de Jesus Ngoma-Kisoko³⁸ Dieudonné Mumba Ngoyi^{38,39}, Modesto Cruz⁴⁰, Celso Hosking⁴⁰, José Jiménez Abreu⁴¹, Christine Varon⁴², Lucie Benejat⁴², Ousman Secka⁴³, Alexander Link⁴⁴, Peter Malfertheiner⁴⁴, Michael Buenor Adinortey⁴⁵, Ansumana Sandy Bockarie⁴⁶, Cynthia Ayefoumi Adinortey⁴⁷, Eric Gyamerah Ofori⁴⁸, Dionyssios N. Sqouras⁴⁹, Beatriz Martinez-Gonzalez⁴⁹, Spyridon Michopoulos⁵⁰, Sotirios Georgopoulos⁵¹, Elisa Hernandez⁵², Braulio Volga Tacatic⁵³, Mynor Aguilar⁵⁴, Ricardo L. Dominguez⁵⁵. Douglas R. Morgan⁵⁶. Hiördis Harðardóttir⁵⁷. Anna Ingibiörg Gunnarsdóttir⁵⁷. Hallgrímur Guðiónsson⁵⁷, Jón Gunnlaugur Jónasson^{57,58}, Einar S. Biörnsson^{57,58}, Mamatha Ballal⁵⁹, Vignesh Shetty^{59,60} Muhammad Miftahussurur⁶¹, Titong Sugihartono⁶¹, Ricky Indra Alfaray⁶¹, Langgeng Agung Waskito⁶¹, Kartika Afrida Fauzia⁶¹, Ari Fahrial Syam⁶², Hasan Maulahela⁶², Reza Malekzadeh⁶³, Masoud Sotoudeh⁶³, Avi Peretz^{64,65}, Maya Azrad^{64,65}, Avi On^{65,66}, Valli De Re⁶⁷, Stefania Zanussi⁶⁷, Renato Cannizzaro⁶⁸, Vincenzo Canzonieri⁶⁹, Takaya Shimura⁷⁰, Kengo Tokunaga⁷¹, Takako Osaki⁷¹, Shigeru Kamiya⁷¹, Khaled Jadallah⁷², Ismail Matalka⁷², Nurbek Igissinov⁷³, Marija Satarovna Moldobaeva⁷⁴, Attokurova Rakhat⁷⁴, Il Ju Choi⁷⁵, Jae Gyu Kim⁷⁶, Nayoung Kim⁷⁷, Minkyo Song⁴, Mārcis Leia^{78,79,80}, Reinis Vangrays⁷⁸, Girts Škenders^{78,80}, Dace Rudzīte⁸⁰, Aiga Rūdule⁷⁸, Aigars Vanags⁷⁹, Ilze Kikuste⁷⁸, Juozas Kupcinskas⁸¹, Jurgita Skieceviciene⁸¹, Laimas Jonaitis⁸¹, Gediminas Kiudelis⁸¹, Paulius Jonaitis⁸¹, Vytautas Kiudelis⁸¹. Greta Varkalaite⁸¹. Jamuna Vadivelu^{82,83}. Mun Fai Loke⁸². Kumutha Malar Vellasamy⁸². Roberto Herrera-Goepfert⁸⁴, Juan Octavio Alonso-Larraga⁸⁵, Than Than Yee⁸⁶, Kyaw Htet⁸⁶, Takeshi Matsuhisa⁸⁷, Pradeep Krishna Shrestha⁸⁸, Shamshul Ansari⁸⁹, Olumide Abiodun⁹⁰, Christopher Jemilohun⁹¹, Kolawole Olusevi Akande⁹², Oluwatosin Olu-Abiodun⁹³, Francis Aiang Magaii⁹⁴, Avodele Omotoso⁹⁵, Chukwuemeka Chukwunwendu Osuagwu⁹⁶, Uchenna Okonkwo⁹⁵, Opeyemi O. Owoseni⁹⁷, Carlos Castaneda⁹⁸, Miluska Castillo⁹⁹. Billie Velapatino¹⁰⁰, Robert H. Gilman¹⁰¹, Pawet Krzyżek¹⁰², Grażyna Gościniak¹⁰², Dorota Pawetka¹⁰³, Izabela Korona-Glowniak 104, Halina Cichoz-Lach 105, Monica Oleastro 106, Ceu Figueiredo 107,108,109, Jose C. Machado 107,108,109 Rui M. Ferreira 107,108 Dmitry S. Bordin 110,111,112 Maria A. Livzan 113, Vladislav V. Tsukanov 114 Patrick Tan^{115,116,117}, Khay Guan Yeoh^{118,119}, Feng Zhu¹¹⁸, Reid Ally^{120,121}, Rainer Haas¹²². Milagrosa Montes¹²³. María Fernández-Reves¹²³ Esther Tamayo¹²³ Jacobo Lizasoain¹²³ Luis Bujanda¹²⁴ Sergio Lario^{125,126} María José Ramírez-Lázaro 125,126, Xavier Calvet 125,126, Eduard Brunet-Mas 125,126, María José Domper-Arnal 127,128 Sandra García-Mateo 127,128, Daniel Abad-Baroia 129, Pedro Delgado-Guillena 130, Leticia Moreira 131, Josep Botarques 132, Isabel Pérez-Martínez^{133,134}, Eva Barreiro-Alonso^{133,135,136}, Virginia Flores¹³⁷, Javier P. Gisbert^{138,139}, Edurne Amorena Muro¹⁴⁰, Pedro Linares¹⁴¹, Vicente Martin¹⁴², Laura Alcoba¹⁴¹, Tania Fleitas-Kanonnikoff¹⁴³ Hisham N, Altaveb144,145, Lars Engstrand146, Helena Enroth147, Peter M, Keller148,149, Karoline Wagner150, Daniel Pohl151, Yi-Chia Lee¹⁵², Jyh-Ming Liou¹⁵², Ming-Shiang Wu¹⁵², Bekir Kocazeybek¹⁵³, Suat Sarıbas¹⁵³, İhsan Tascı¹⁵⁴ Süleyman Demiryas¹⁵⁴, Nuray Kepil¹⁵⁵, Luis Quiel¹⁵⁶, Miguel Villagra¹⁵⁷, Morgan Norton¹⁵⁸, Deborah Johnson¹⁵⁸ Robert J. Huang¹⁵⁹, Joo Ha Hwang¹⁵⁹, Wendy Szymczak¹⁶⁰, Saranathan Rajagopalan¹⁶⁰, Emmanuel Asare¹⁶⁰, William R. Jacobs Jr. 160, Haejin In 160,161, Roni Bollag 162, Aileen Lopez 162, Edward J. Kruse 163, Joseph White 163, David Y. Graham¹⁶⁴, Charlotte Lane¹⁶⁵, Yang Gao¹⁶⁵, Patricia I. Fields¹⁶⁵, Benjamin D. Gold¹⁶⁶, Marcia Cruz-Correa^{167,168} María González-Pons¹⁶⁷, Luz M. Rodriguez¹⁶⁹, Vo Phuoc Tuan¹⁷⁰, Ho Dang Quy Dung¹⁷⁰, Tran Thanh Binh¹⁷⁰ Tran Thi Huyen Trang¹⁷¹, Vu Van Khien¹⁷¹, Xiongfong Chen¹⁷², Castle Raley¹⁷³, Bailey Kessing¹⁷³, Yongmei Zhao¹⁷², Bao Tran¹⁷³, Andrés J. Gutiérrez-Escobar⁴, Yunhu Wan³, Belynda Hicks³, Bin Zhu³, Kai Yu⁴, Bin Zhu⁴, Meredith Yeager³, Amy Hutchinson³, Kedest Teshome³, Kristie Jones³, Wen Luo³, Quentin Jehanne⁴², Yukako Katsura¹⁷⁴, Patricio Gonzalez-Hormazabal¹⁷⁵, Xavier Didelot¹⁷⁶, Sam Sheppard¹⁷⁷, Eduardo Tarazona-Santos¹⁷⁸, Leonardo Mariño-Ramírez¹⁷⁹, John T. Loh¹⁰, Steffen Backert¹⁸⁰, Michael Naumann¹⁸¹, Christian C. Abnet⁴, Annemieke Smet 182, Douglas E, Berg 183, Álvaro Chiner-Oms 184, 185, Iñaki Comas 185, 186, Francisco José Martínez-Martínez 186, Roxana Zamudio^{178,187}, Philippe Lehours⁴², Francis Megraud⁴², Koji Yahara¹⁸⁸, Martin J. Blaser¹⁸⁹, Tamas Vincze¹⁹⁰ Richard D. Morgan¹⁹⁰, Richard J. Roberts¹⁹⁰, Stephen J. Chanock⁴, John P. Dekker¹⁹¹, Javier Torres¹⁹² Timothy L. Cover^{10,193}, Mehwish Noureen¹⁹⁴, Wolfgang Fischer¹²², Filipa F, Vale^{195,196}, Joshua L, Cherry^{197,198} Naoki Osada¹⁹⁹, Masaki Fukuyo²⁰⁰, Masanori Arita²⁰¹, Yoshio Yamaoka^{14,164}, Ichizo Kobayashi²⁰², Ikuo Uchiyama²⁰³, Daniel Falush @ ⁹, M. Constanza Camargo @ ^{4,205} & Charles S. Rabkin^{4,205}




H. pylori Genome Project


- 1011 H. pylori strains collected from people with:
 - Non-atrophic gastritis (N=606)
 - Advanced intestinal metaplasia (N=172)
 - Gastric cancer (N=233)
- Primary manuscripts in preparation:
 - H. pylori resistance to antibiotics
 - Characterization of plasmids
 - GWAS of gastric cancer and intestinal metaplasia
- Epigenomes of 1011 Hp strains still in process

Gene content, phage cycle regulation model and prophage inactivation disclosed by prophage genomics in the *Helicobacter pylori* Genome Project

Filipa F. Vale na, HpGP Research Network*, Richard J. Roberts^c, Ichizo Kobayashi^{d,e,f,g}, M. Constanza Camargo^{h#}, and Charles S. Rabkin^{h#}



GUT MICROBES 2024, VOL. 16, NO. 1, 2379440 https://doi.org/10.1080/19490976.2024.2379440



African Helicobacter pylori Genome Project



 At least 80% of the continent (n=1000 individuals) using mainly string test (EnteroTrack)


 Collaboration with the African Helicobacter and Microbiota Study Group

Microbiome component

Novel Device to Sample the Esophageal Microbiome— The Esophageal String Test

Sophie A. Fillon^{1,9}*, J. Kirk Harris^{2,9}, Brandie D. Wagner³, Caleb J. Kelly¹, Mark J. Stevens², Wendy Moore¹, Rui Fang³, Shauna Schroeder¹, Joanne C. Masterson¹, Charles E. Robertson⁴, Norman R. Pace⁴, Steven J. Ackerman⁵, Glenn T. Furuta¹

PLOS ONE | www.plosone.org | September 2012 | Volume 7 | Issue 9 | e42938



EnteroTrack Device

- String encapsulated in gelating
- Different string lengths designed to sample the esophagus, + stomach, +duodenum
- FDA approved for monitoring eosinophilic esophagitis via protein assays without endoscopy
- Testing utility for Hp retrieval and culture

Concept:

- Perform EnteroTrack exam
- Preserve samples
- Transfer to central labs for processing
- Sequencing

Join Our Team

Division of Cancer Epidemiology and Genetics





Visit dceg.cancer.gov

What types of Careers?

Tenure-Track and Tenure-Eligible PIs

What types of fellowship?

Postdoctoral, predoctoral, postbaccalaureate, summer internships



www.cancer.gov/espanol